FindTrial
Sign In

To study the Expression of CLAUDIN 4 and PARP in BRCA1 and NON-BRCA1 Epithelial ovarian cancers using a method called immunohistochemistry

Expression of CLAUDIN 4 and PARP in BRCA1 and NON-BRCA1 Epithelial ovarian cancers: An immunohistochemical study - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/104364
Enrollment
30
Registered
2026-02-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C569- Malignant neoplasm of unspecifiedovary

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Nil: Nil

Sponsors

Maulana Azad Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed female patients of Epithelial ovarian carcinoma whose specimens are received in department of Pathology,MAMC

Exclusion criteria

Exclusion criteria: Other types of ovarian carcinoma -Germ cell,sex cord stromal Patients with prior radiation therapy and or neoadjuvant chemotherapy

Design outcomes

Primary

MeasureTime frame
Proportion of cases with BRCA1 positivity Proportion of cases showing Claudin4 positivity Proportion of cases showing PARP positivityTimepoint: Baseline—

Secondary

MeasureTime frame
Association of Claudin4 with PARP Association of Claudin4 & PARP with BRCA1 positivity Association of BRCA1,PARP & Claudin4 with emphasis on histological type,grade, clinical stageTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr Reena Tomar

Maulana Azad Medical College

drreenat@yahoo.com9711972630

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026